Skip to main content
PMC home page
BMC Pulmonary Medicine logoLink to BMC Pulmonary Medicine
. 2021 Oct 15;21:320. doi: 10.1186/s12890-021-01692-3

Prediction of readmission in patients with acute exacerbation of chronic obstructive pulmonary disease within one year after treatment and discharge

Lili Chen 1, Shiping Chen 1,✉
PMCID: PMC8518323  PMID: 34654406

Abstract

Background

To investigate the risk factors and construct a logistic model and an extreme gradient boosting (XGBoost) model to compare the predictive performances for readmission in acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients within one year.

Methods

In total, 636 patients with AECOPD were recruited and divided into readmission group (n = 449) and non-readmission group (n = 187). Backward stepwise regression method was used to analyze the risk factors for readmission. Data were divided into training set and testing set at a ratio of 7:3. Variables with statistical significance were included in the logistic model and variables with P < 0.1 were included in the XGBoost model, and receiver operator characteristic (ROC) curves were plotted.

Results

Patients with acute exacerbations within the previous 1 year [odds ratio (OR) = 4.086, 95% confidence interval (CI) 2.723–6.133, P < 0.001), long-acting β agonist (LABA) application (OR = 4.550, 95% CI 1.587–13.042, P = 0.005), inhaled corticosteroids (ICS) application (OR = 0.227, 95% CI 0.076–0.672, P = 0.007), glutamic-pyruvic transaminase (ALT) level (OR = 0.985, 95% CI 0.971–0.999, P = 0.042), and total CAT score (OR = 1.091, 95% CI 1.048–1.136, P < 0.001) were associated with the risk of readmission. The AUC value of the logistic model was 0.743 (95% CI 0.692–0.795) in the training set and 0.699 (95% CI 0.617–0.780) in the testing set. The AUC value of XGBoost model was 0.814 (95% CI 0.812–0.815) in the training set and 0.722 (95% CI 0.720–0.725) in the testing set.

Conclusions

The XGBoost model showed a better predictive value in predicting the risk of readmission within one year in the AECOPD patients than the logistic regression model. The findings of our study might help identify patients with a high risk of readmission within one year and provide timely treatment to prevent the reoccurrence of AECOPD.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12890-021-01692-3.

Keywords: Acute exacerbation of chronic obstructive pulmonary disease, Readmission, Logistic model, XGBoost model

Background

Chronic obstructive pulmonary disease (COPD) is a disease associated with chronic airway inflammation, characterized by persistent respiratory symptoms and airflow limitations [1]. COPD is the fourth major cause of death and may rise to the third leading cause of death by 2030 according to the prediction of the World Health Organization [2]. A national cross-sectional study in 2018 investigated the lung health status of adults > 20 years old in 10 provinces of China, and showed that the prevalence of COPD in adults > 20 years old was 8.6%, in adults > 40 years old was as high as 13.7%, causing a significant disease burden [3]. Acute exacerbation of COPD (AECOPD) refers to the aggravation of respiratory symptoms in patients, which is the main reason for hospitalization and medical expenditure of COPD patients [1, 4]. Approximately 63% of COPD patients have at least one readmission due to exacerbation within 1 year after hospitalization [5, 6]. AECOPD accelerate the progress of the disease, reduce the quality of life of patients and increase the risk of death [7]. Early identification of patients with high risk of AECOPD and readmission and timely interventions to reduce the incidence of AECOPD and readmission are of great clinical significance for improving the prognosis of COPD patients and delaying the progression of the disease.

Previously, the risk factors associated with AECOPD and readmission in patients were explored by several studies, which revealed that gender, hospital stay, medical aid care, duration of systemic steroid use were factors leading to the AECOPD and readmission [8]. Factors including age, tobacco use, diabetes mellitus, infections, obesity, and frequency of hospital visit were also reported to influencing the occurrence of AECOPD and readmission [9]. Currently, there was no international universal prediction model for predicting the readmission of AECOPD patients within one year after discharge. Prediction models of readmission in patients with AECOPD were established based on the data of USA or UK people and some of them were focused on predicting the risk of readmission of AECOPD patients within 30 days based on social factors or LACE index (length of stay, acuity of admission, co-morbidities, and emergency department visits within the last 6 months) [10, 11]. Additionally, the prediction models for readmission of AECOPD patients within 90 days were also established based on PEARL (previous admissions, eMRCD score, Age, Right-sided heart failure and Left-sided heart failure) or COPD-2-HOME score (CAT score, hyperinflation, obstruction, prior admission, eosinophilia) [12, 13]. A prediction model of readmission of AECOPD patients within 90 days considered the importance of multimorbidity, frailty and poor socioeconomic status in patients [14]. Njoku et al. [15] indicated that the prevalence of COPD-related readmission was about 2.6–82.2% within 30 days, 11.8–44.8% at 31–90 days, 17.9–63.0% at 6 months, and 25.0–87.0% at 12-month post-discharge [15], which suggested that the importance of not only predicted the readmission of AECOPD patients within 30 days or 90 days, but also one year. At present, a prediction model for one-year readmission of COPD patients was established but it had a low area under the curve (AUC) value and lacked validation of the results [16]. There was no prediction model for predicting the readmission of AECOPD patients within one year after discharge based on the data from Chinese population. To establish a prediction model for predicting the readmission of AECOPD patients within one year after discharge in China is of great value.

Gradient boosting machine (GBM) is a kind of machine learning algorithm helping assemble the weak learners into a strong learner. GBM increases the performance of the prediction model during the gradient descent process. The extreme gradient boosting (XGBoost) model is an extension of GBM, which combines several learning algorithms to achieve a better predictive performance than any of the constituent learning algorithms alone [17]. XGBoost applies a second-order Taylor expansion to the loss function and simultaneously implements the first derivative and the second derivative. Additionally, a regularization term is supplemented in the objective function to increase the generalizability of a single tree and decrease the complexity of the objective function [18]. XGBoost model is widely used for disease diagnosis and prediction due to its fast speed, excellent classification effect.

In our study, we collected the data of 650 patients with AECOPD from the Second Affiliated Hospital of Nanjing Medical University from Jan. 2016 to Dec. 2019 to investigate the risk factors and construct XGBoost model and logistic regression model to compare the predictive performance for readmission in AECOPD patients within one year after treatment and discharge.

Methods

Study population

In the current study, 650 patients with AECOPD were recruited from the Second Affiliated Hospital of Nanjing Medical University between Jan. 2016 and Dec. 2019. The data of the patients were retrospectively extracted from a broad coding records search and review of COPD assessments routinely completed by clinicians or nurses. After excluding 12 patients who readmitted into hospitals because of pneumonia, 1 patient who readmitted into hospitals due to congestive heart failure and 1 patient who readmitted into hospitals due to perianal condyloma acuminatum, 636 participants were finally included. A hospitalization for AECOPD was identified through International Classification of Diseases-10 codes (J44.1) [19]. Readmission one year after discharge means within one year from their first day of discharge to readmission day [20]. All subjects were divided into readmission group (n = 187) and non-readmission group (n = 449). This study got the approval from the Ethics Committee of from the Second Affiliated Hospital of Nanjing Medical University, the approval number was (No. [2021]-KY-091-01). The screen process of the participants was shown in Fig. 1.

Fig. 1.

Fig. 1

Open in a new tab

The screen process of the participants in this study

Data collection

The data of participants were collected to analyze the risk factors of readmission within one year. The gender, age (years), body mass index (BMI, kg/m2), acute exacerbation in previous 1 year, smoking status, daily amount of smoking, duration of smoking, number of years of smoking packets, the application of long-acting muscarinic antagonist (LAMA), long-acting β agonist (LABA), short-acting muscarinic antagonist (SAMA), short-acting β agonist (SABA), phosphodiesterase 4 inhibitor (PDE4I), inhaled corticosteroids (ICS), history of congestive heart-failure, diabetes, hypertension, atrial fibrillation and combined with other disease were collected during the recruit time. The systolic blood pressure (mmHg), diastolic blood pressure (mmHg), respiratory rate (time/minute), temperature (℃), heart rate (time/minute), hemoglobin (Hb, g/L), red blood cells (RBC, 1012/L), white blood cells (WBC, 109/L), platelets (PLT, 109/L), neutrophil count (NEUT, 109/L), percentage of neutrophils (%), lymphocyte count (LYM, 109/L), percentage of lymphocytes (%), monocytes count (MONO, 109/L), percentage of monocytes (%), eosinophil count (EOS, 109/L), percentage of eosinophils (%), red blood cell distribution width (RDW), glutamic-pyruvic transaminase (ALT, μ/L), glutamic oxalacetic transaminase (AST, μ/L), total bilirubin (TBIL, μmol/L), albumin (ALB; g/L), blood urea nitrogen (BUN; μmol/L), creatinine (Cr, μmol/L), uric acid (μmol/L), hypersensitive C-reactive protein (mg/dL), modified Medical Research Council (mMRC) grade, and total COPD assessment test (CAT) score were collected at admission. The data on forced expiratory volume in 1 s (FEV1, mL), forced vital capacity (FVC, mL), FEV1/FVC, FEV1 in predicted value FEV1, the use of systemic glucocorticoid, antibacterial agents, oxygen therapy, and mechanical ventilation were collected during the treatment. During the 12 months ± 30 days’ follow-up, if readmission occurred, the readmission frequency and reasons were recorded.

Definitions of the variables

Congestive heart failure referred to the symptoms and/or signs of present heart failure, and left ventricular ejection fraction (LVEF) < 40%; or LVEF ≥ 40% with elevated brain natriuretic peptide and meeting at least one of the following requirements: (1) left ventricular hypertrophy and/or left atrial enlargement; (2) abnormal diastolic function.

Diabetes was defined as patients with blood glucose level ≥ 11.1 mmol/L at any time after meal or fasting blood glucose level ≥ 7.0 mmol/L, or having blood glucose level ≥ 11.1 mmol/L in 2-h glucose tolerance test or glycosylated hemoglobin ≥ 6.3%.

Hypertension was defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg when blood pressure was measured three times on different days without using antihypertensive drugs; For patients with a history of hypertension and currently taking antihypertensive drugs, they were diagnosed with hypertension although the blood pressure was lower than 140/90 mmHg.

Smoking status: including never smoking, former smoking and current smoking. Non-smoking was defined as less than 100 cigarettes in a lifetime, former smoking referred to more than 1 year of smoking cessation, and number of years of smoking packets = number of smoking packets per day (20 cigarettes are counted as 1 packet) × smoking years [21].

XGBoost model

XGBoost model is an ensemble learning algorithm based on the gradient-boosted tree algorithm. XGBoost model processes sparse data via a sparsity-aware learning algorithm and weights quantile sketch to approximate tree learning [22].

Statistical analysis

All statistical tests were conducted by two-sided test. The measurement data of normal distribution were described by Mean ± standard deviation (Mean ± SD), the independent sample t test was applied for comparisons between groups. The non-normal distributed data were expressed by median and quaternary spacing [M (Q1, Q3)], and differences between groups were compared by the Mann–Whitney U rank sum test. The enumeration data were shown as n (%). Chi-square test or Fisher’s exact probability method was used for comparison between groups. Random forest filling method was applied for filling in missing values with 100 trees via the missForest package in R© Version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria) [23]. Sensitivity analysis was performed before and after interpolation. To explore the risk factors for readmission in AECOPD patients within one year, the differences were firstly analyzed between groups, and the variables with statistical significance were included in the multivariate logistic model. Backward stepwise regression method was used to analyze the risk factors for readmission. For the establishment of prediction models, 70% of the samples were involved as the training set for construction of the models, and 30% of the samples were used as the testing set to test the diagnostic efficiency of the models [24, 25], and the equilibria analysis was conducted between the training set and the testing set. Variables with P < 0.1 were included in the logistic model and the extreme gradient boosting (XGBoost) model, and the parameters were adjusted. After establishing the models, the area under the curve (AUC) value, kolmogorov–smirnov (KS), sensitivity, specificity and accuracy were used to evaluate the performance of models. The receiver operator characteristic (ROC) curves were plotted. SAS 9.4 and R 3.6 were employed for data analysis in our study, and P < 0.05 referred to be statistical significant.

Results

The manipulation of missing data

Variables with a missing value ratio of more than 25% were removed (most of them were data related to discharge including partial arterial oxygen pressure, partial pressure of carbon dioxide in artery, arterial oxygenation, pH, and medications at discharge), and random forest filling method was used to fill in missing values for selected data. Sensitivity analysis before and after interpolation was shown in Table 1. There was no bias after interpolation of the missing data.

Table 1.

Sensitivity analysis of the data before and after interpolation

Variable Before interpolation (n = 636) After interpolation (n = 636) Statistical magnitude P
Gender, n (%) χ2 = 0.000 1.000
 Male 425 (66.82) 425 (66.82)
 Female 211 (33.18) 211 (33.18)
Age, mean ± SD 70.82 ± 9.88 70.82 ± 9.88 t = 0.000 1.000
Height, mean ± SD 1.67 ± 0.07 1.67 ± 0.07 t = 0.000 1.000
Weight, mean ± SD 65.50 ± 8.44 65.50 ± 8.44 t = 0.000 1.000
Acute exacerbation in previous 1 year, n (%) χ2 = 0.000 1.000
 No 430 (67.61) 430 (67.61)
 Yes 206 (32.39) 206 (32.39)
Smoking status, n(%) χ2 = 0.000 1.000
 Never smoked 321 (50.47) 321 (50.47)
 Smoked before 93 (14.62) 93 (14.62)
 Smoker at present 222 (34.91) 222 (34.91)
  Daily amount of smoking, M (Q1, Q3) 0.00 (0.00, 15.00) 0.00 (0.00, 15.00) Z = 0.000 1.000
  Duration of smoking, M (Q1, Q3) 0.00 (0.00, 30.00) 0.00 (0.00, 30.00) Z = 0.000 1.000
LAMA, n (%) χ2 = 0.000 1.000
 No 479 (75.31) 479 (75.31)
 Yes 157 (24.69) 157 (24.69)
SAMA, n (%) χ2 = 0.000 1.000
 No 634 (99.69) 634 (99.69)
 Yes 2 (0.31) 2 (0.31)
LABA, n (%) χ2 = 0.000 1.000
 No 413 (64.94) 413 (64.94)
 Yes 223 (35.06) 223 (35.06)
SABA, n (%) χ2 = 0.000 1.000
 No 555 (87.26) 555 (87.26)
 Yes 81 (12.74) 81 (12.74)
PDE4I, n (%) χ2 = 0.000 1.000
 No 617 (97.01) 617 (97.01)
 Yes 19 (2.99) 19 (2.99)
ICS, n (%) χ2 = 0.000 1.000
 No 422 (66.35) 422 (66.35)
 Yes 214 (33.65) 214 (33.65)
Congestive heart-failure, n (%) χ2 = 0.000 1.000
 No 572 (89.94) 572 (89.94)
 Yes 64 (10.06) 64 (10.06)
Diabetes, n (%) χ2 = 0.000 1.000
 No 498 (78.30) 498 (78.30)
 Yes 138 (21.70) 138 (21.70)
Hypertension, n (%) χ2 = 0.000 1.000
 No 280 (44.03) 280 (44.03)
 Yes 356 (55.97) 356 (55.97)
Atrial fibrillation, n (%) χ2 = 0.000 1.000
 No 596 (93.71) 596 (93.71)
 Yes 40 (6.29) 40 (6.29)
Combined with other diseases, n (%) χ2 = 0.000 1.000
 No 432 (67.92) 432 (67.92)
 Yes 204 (32.08) 204 (32.08)
Systolic blood pressure, Mean ± SD 133.46 ± 17.34 133.46 ± 17.34 t = 0.000 1.000
Diastolic blood pressure, Mean ± SD 78.73 ± 10.82 78.73 ± 10.82 t = 0.000 1.000
Respiratory rate, Mean ± SD 19.28 ± 2.53 19.28 ± 2.53 t = 0.000 1.000
Temperature, mean ± SD 36.86 ± 0.56 36.86 ± 0.56 t = 0.000 1.000
Heart rate, mean ± SD 81.65 ± 11.35 81.65 ± 11.35 t = 0.000 1.000
Hb, mean ± SD 132.50 ± 17.34 132.51 ± 17.26 t =  − 0.002 0.998
RBC, mean ± SD 4.33 ± 0.55 4.33 ± 0.55 t = 0.046 0.963
WBC, M (Q1, Q3) 6.89 (5.51, 8.97) 6.90 (5.53, 8.93) Z =  − 0.027 0.979
PLT, M (Q1, Q3) 188.00 (151.00, 235.75) 188.50 (151.75, 235.00) Z =  − 0.043 0.966
NEUT, M (Q1, Q3) 4.67 (3.52, 6.65) 4.68 (3.53, 6.65) Z =  − 0.044 0.965
Percentage of neutrophils, mean ± SD 70.51 ± 11.70 70.54 ± 11.65 t =  − 0.052 0.959
LYM, M (Q1, Q3) 1.28 (0.90, 1.80) 1.29 (0.91, 1.80) Z =  − 0.079 0.937
Percentage of lymphocytes, M (Q1, Q3) 19.40 (12.40, 27.30) 19.43 (12.47, 27.13) Z = 0.019 0.985
MONO, M (Q1, Q3) 0.44 (0.33, 0.60) 0.44 (0.33, 0.60) Z =  − 0.066 0.947
Percentage of monocytes, M (Q1, Q3) 6.30 (4.90, 8.10) 6.30 (4.90, 8.00) Z = 0.045 0.964
EOS, M (Q1, Q3) 0.10 (0.03, 0.19) 0.10 (0.03, 0.19) Z =  − 0.036 0.971
Percentage of eosinophils, M(Q1, Q3) 1.50 (0.40, 2.90) 1.46 (0.40, 2.90) Z = 0.018 0.986
RDW, mean ± SD 13.20 ± 1.07 13.20 ± 1.05 t =  − 0.020 0.984
ALT, M (Q1, Q3) 15.45 (10.93, 23.00) 15.50 (11.00, 23.00) Z =  − 0.027 0.978
AST, M (Q1, Q3) 18.00 (14.00, 23.17) 18.00 (14.00, 23.10) Z =  − 0.026 0.979
TBIL, M (Q1, Q3) 9.30 (6.65, 13.35) 9.35 (6.70, 13.30) Z =  − 0.013 0.989
ALB, mean ± SD 39.88 ± 4.68 39.89 ± 4.67 t =  − 0.035 0.972
BUN, M (Q1, Q3) 5.44 (4.44, 6.68) 5.44 (4.45, 6.68) Z =  − 0.014 0.989
Cr, M (Q1, Q3) 76.00 (64.10, 93.90) 76.20 (64.40, 93.75) Z =  − 0.037 0.971
Uric acid, M (Q1, Q3) 288.00 (226.00, 352.00) 288.50 (226.00, 352.00) Z =  − 0.009 0.993
Hypersensitive C-reactive protein, M (Q1, Q3) 8.30 (2.00, 38.00) 8.40 (2.00, 36.67) Z =  − 0.655 0.512
mMRC grade, n (%) Z = 0.000 1.000
 0 1 (0.16) 1 (0.16)
 1 138 (21.70) 138 (21.70)
 2 279 (43.87) 279 (43.87)
 3 189 (29.72) 189 (29.72)
 4 29 (4.56) 29 (4.56)
FEV1, M (Q1, Q3) 1.60 (1.10, 2.21) 1.60 (1.10, 2.21) Z = 0.000 1.000
FVC, M (Q1, Q3) 2.26 (1.66, 3.64) 2.26 (1.66, 3.64) Z = 0.000 1.000
FEV1/FVC, mean ± SD 67.25 ± 13.27 67.25 ± 13.27 t = 0.000 1.000
FEV1 in predicted value FEV1, mean ± SD 55.33 ± 17.82 55.33 ± 17.82 t = 0.000 1.000
Use of systemic glucocorticoid, n (%) χ2 = 0.000 1.000
 No 472 (74.21) 472 (74.21)
 Yes 164 (25.79) 164 (25.79)
Antibacterial agents, n (%) χ2 = 0.000 1.000
 No 13 (2.04) 13 (2.04)
 Yes 623 (97.96) 623 (97.96)
Oxygen therapy, n (%) χ2 = 0.000 1.000
 No 126 (19.81) 126 (19.81)
 Yes 510 (80.19) 510 (80.19)
Mechanical ventilation, n (%) χ2 = 0.000 1.000
 No 628 (98.74) 628 (98.74)
 Noninvasive ventilation 8 (1.26) 8 (1.26)
Group, n (%) χ2 = 0.000 1.000
 Non-readmission group 449 (70.60) 449 (70.60)
 Readmission group 187 (29.40) 187 (29.40)
BMI, mean ± SD 23.48 ± 2.95 23.48 ± 2.95 t = 0.000 1.000
CAT score, mean ± SD 20.28 ± 5.34 20.28 ± 5.34 t = 0.000 1.000
Open in a new tab

LAMA long-acting muscarinic antagonist, LABA long-acting β agonist, SAMA short-acting muscarinic antagonist, SABA short-acting β agonist, PDE4I phosphodiesterase 4 inhibitor, ICS inhaled corticosteroids, Hb hemoglobin, RBC red blood cells, WBC white blood cells, PLT platelets, NEUT neutrophil count, LYM lymphocyte count, MONO monocytes count, EOS eosinophil count, RDW red blood cell distribution width, ALT glutamic-pyruvic transaminase, AST glutamic oxalacetic transaminase, TBIL total bilirubin, ALB albumin, BUN blood urea nitrogen, Cr creatinine, mMRC modified Medical Research Council, CAT COPD assessment test, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity

Comparisons of baseline data between readmission group and non-readmission group

As exhibited in Table 2, the age (72.21 years vs. 70.24 years, t =  − 2.295, P = 0.022), MONO counts (0.48 109/L vs. 0.43 109/L, Z = 2.438, P = 0.015), mMRC grade (t = 5.963, P < 0.001), total CAT score (22,04 vs. 19.55, t =  − 5.475, P < 0.001), the proportions of patients with acute exacerbation in previous 1 year (54.01% vs. 23.39%, χ2 = 56.542, P < 0.001), patients using LAMA (32.09% vs. 21.60%, χ2 = 7.802, P = 0.005), LABA (47.06% vs. 30.07%, χ2 = 16.741, P < 0.001), ICS (43.32% vs. 29.62%, χ2 = 11.089, P < 0.001), and patients receiving systemic glucocorticoids (32.62% vs. 22.94%, χ2 = 6.465, P = 0.011), oxygen therapy (85.03% vs. 78.17%, χ2 = 3.903, P = 0.048) and mechanical ventilation (2.67% vs. 0.67%, χ2 = 4.276, P = 0.039) in the readmission group were higher than in the non-readmission group. The percentage of lymphocytes (17.60 vs. 19.80, Z =  − 2.031, P = 0.042), ALT (13.30 μ/L vs. 16.22 μ/L, Z =  − 3.176, P = 0.002), AST (16.50 μ/L vs. 19.00 μ/L, Z =  − 2.896, P = 0.004), FEV1/FVC (63.36 vs. 68.87, t = 4.845, P < 0.001) and the predicted value of FEV1 (52.60 vs. 58.40, Z =  − 3.076, P = 0.002) in the readmission group were lower than in the non-readmission group.

Table 2.

Comparisons of characteristics of patients between readmission group and non-readmission group

Variable Description (n = 636) Non-readmission group (n = 449) Readmission group (n = 187) Statistical magnitude P
Gender, n (%) χ2 = 2.208 0.137
 Male 425 (66.82) 292 (65.03) 133 (71.12)
 Female 211 (33.18) 157 (34.97) 54 (28.88)
Age, mean ± SD 70.82 ± 9.88 70.24 ± 9.73 72.21 ± 10.09 t =  − 2.295 0.022
BMI, mean ± SD 23.48 ± 2.95 23.50 ± 2.93 23.41 ± 2.99 t = 0.375 0.708
Acute exacerbation in previous 1 year, n (%) χ2 = 56.542  < 0.001
 No 430 (67.61) 344 (76.61) 86 (45.99)
 Yes 206 (32.39) 105 (23.39) 101 (54.01)
Smoking status, n(%) Z =  − 1.393 0.164
 Never smoked 321 (50.47) 220 (49.00) 101 (54.01)
 Smoked before 93 (14.62) 64 (14.25) 29 (15.51)
 Smoker at present 222 (34.91) 165 (36.75) 57 (30.48)
  Daily amount of smoking, M (Q1, Q3) 0.00 (0.00, 15.00) 0.00 (0.00, 15.00) 0.00 (0.00, 10.00) Z =  − 1.499 0.134
  Duration of smoking, M (Q1, Q3) 0.00 (0.00, 30.00) 0.00 (0.00, 30.00) 0.00 (0.00, 30.00) Z =  − 1.496 0.135
  Number of years of smoking packets, M (Q1, Q3) 0.00 (0.00, 21.00) 0.00 (0.00, 25.00) 0.00 (0.00, 20.00) Z =  − 1.597 0.110
LAMA, n(%) χ2 = 7.802 0.005
 No 479 (75.31) 352 (78.40) 127 (67.91)
  Yes 157 (24.69) 97 (21.60) 60 (32.09)
SAMA, n(%) χ2 = 0.410 0.522
 No 634 (99.69) 448 (99.78) 186 (99.47)
 Yes 2 (0.31) 1 (0.22) 1 (0.53)
LABA, n(%) χ2 = 16.741  < 0.001
 No 413 (64.94) 314 (69.93) 99 (52.94)
 Yes 223 (35.06) 135 (30.07) 88 (47.06)
SABA, n(%) χ2 = 0.993 0.319
 No 555 (87.26) 388 (86.41) 167 (89.30)
 Yes 81 (12.74) 61 (13.59) 20 (10.70)
PDE4I, n(%) χ2 = 0.045 0.833
 No 617 (97.01) 436 (97.10) 181 (96.79)
 Yes 19 (2.99) 13 (2.90) 6 (3.21)
ICS, n(%) χ2 = 11.089  < 0.001
 No 422 (66.35) 316 (70.38) 106 (56.68)
 Yes 214 (33.65) 133 (29.62) 81 (43.32)
Congestive heart-failure, n (%) χ2 = 0.399 0.528
 No 572 (89.94) 406 (90.42) 166 (88.77)
 Yes 64 (10.06) 43 (9.58) 21 (11.23)
Diabetes, n (%) χ2 = 0.008 0.929
 No 498 (78.30) 352 (78.40) 146 (78.07)
 Yes 138 (21.70) 97 (21.60) 41 (21.93)
Hypertension, n (%) χ2 = 1.650 0.199
 No 280 (44.03) 205 (45.66) 75 (40.11)
 Yes 356 (55.97) 244 (54.34) 112 (59.89)
Atrial fibrillation, n (%) χ2 = 0.197 0.657
 No 596 (93.71) 422 (93.99) 174 (93.05)
 Yes 40 (6.29) 27 (6.01) 13 (6.95)
Combined with other diseases, n (%) χ2 = 0.034 0.855
 No 432 (67.92) 304 (67.71) 128 (68.45)
 Yes 204 (32.08) 145 (32.29) 59 (31.55)
Systolic blood pressure, mean ± SD 133.46 ± 17.34 133.57 ± 17.48 133.18 ± 17.01 t = 0.258 0.796
Diastolic blood pressure, mean ± SD 78.73 ± 10.82 78.87 ± 10.99 78.40 ± 10.40 t = 0.496 0.620
Respiratory rate, mean ± SD 19.28 ± 2.53 19.20 ± 2.52 19.47 ± 2.53 t =  − 1.203 0.229
Temperature, mean ± SD 36.86 ± 0.56 36.87 ± 0.59 36.84 ± 0.46 t = 0.783 0.434
Heart rate, mean ± SD 81.65 ± 11.35 81.83 ± 11.85 81.22 ± 10.06 t = 0.616 0.538
Hb, mean ± SD 132.51 ± 17.26 132.80 ± 17.22 131.79 ± 17.32 t = 0.678 0.498
RBC, mean ± SD 4.33 ± 0.55 4.35 ± 0.56 4.28 ± 0.51 t = 1.386 0.166
WBC, M (Q1, Q3) 6.90 (5.53, 8.93) 6.89 (5.50, 8.83) 7.01 (5.71, 9.07) Z = 0.922 0.356
PLT, M (Q1, Q3) 188.50 (151.75, 235.00) 190.00 (152.00, 234.00) 183.00 (149.50, 240.00) Z =  − 0.627 0.531
NEUT, M (Q1, Q3) 4.68 (3.53, 6.65) 4.64 (3.43, 6.65) 4.96 (3.82, 6.62) Z = 1.334 0.182
Percentage of neutrophils, mean ± SD 70.54 ± 11.65 70.20 ± 11.65 71.37 ± 11.60 t =  − 1.152 0.250
LYM, M (Q1, Q3) 1.29 (0.91, 1.80) 1.33 (0.92, 1.81) 1.23 (0.85, 1.67) Z =  − 1.389 0.165
Percentage of lymphocytes, M (Q1, Q3) 19.42 (12.47, 27.13) 19.80 (13.30, 27.80) 17.60 (11.25, 25.25) Z =  − 2.031 0.042
MONO, M (Q1, Q3) 0.44 (0.33, 0.60) 0.43 (0.33, 0.58) 0.48 (0.34, 0.67) Z = 2.438 0.015
Percentage of monocytes, M (Q1, Q3) 6.30 (4.90, 8.00) 6.20 (4.90, 7.90) 6.50 (5.30, 8.30) Z = 1.451 0.147
EOS, M (Q1, Q3) 0.10 (0.03, 0.19) 0.10 (0.03, 0.19) 0.10 (0.03, 0.19) Z = 0.048 0.962
Percentage of eosinophils, M(Q1, Q3) 1.46 (0.40, 2.90) 1.47 (0.40, 2.90) 1.45 (0.40, 3.05) Z = 0.007 0.995
RDW, Mean ± SD 13.20 ± 1.05 13.16 ± 1.03 13.29 ± 1.08 t =  − 1.342 0.180
ALT, M (Q1, Q3) 15.50 (11.00, 23.00) 16.22 (11.10, 25.00) 13.30 (9.80, 19.95) Z =  − 3.176 0.002
AST, M (Q1, Q3) 18.00 (14.00, 23.10) 19.00 (14.70, 23.80) 16.50 (13.40, 21.30) Z =  − 2.896 0.004
TBIL, M (Q1, Q3) 9.35 (6.70, 13.30) 9.60 (6.90, 13.60) 8.70 (6.35, 12.30) Z =  − 1.947 0.052
ALB, Mean ± SD 39.89 ± 4.67 40.03 ± 4.73 39.55 ± 4.50 t = 1.198 0.231
BUN, M (Q1, Q3) 5.44 (4.45, 6.68) 5.45 (4.48, 6.66) 5.43 (4.39, 6.81) Z = 0.053 0.958
Cr, M (Q1, Q3) 76.20 (64.40, 93.75) 75.40 (64.80, 90.90) 78.80 (63.70, 98.15) Z = 1.099 0.272
Uric acid, M (Q1, Q3) 288.50 (226.00, 352.00) 292.00 (229.00, 351.00) 280.00 (224.50, 352.00) Z =  − 0.121 0.903
Hypersensitive C-reactive protein, M (Q1, Q3) 8.40 (2.00, 36.67) 7.20 (2.00, 38.00) 9.70 (2.15, 33.20) Z = 0.429 0.668
mMRC grade, n (%) Z = 5.763  < 0.001
 0 1 (0.16) 0 (0.00) 1 (0.22)
 1 138 (21.70) 22 (11.76) 116 (25.84)
 2 279 (43.87) 73 (39.04) 206 (45.88)
 3 189 (29.72) 75 (40.11) 114 (25.39)
 4 29 (4.56) 17 (9.09) 12 (2.67)
CAT score, Mean ± SD 20.28 ± 5.34 19.55 ± 5.02 22.04 ± 5.67 t =  − 5.475  < 0.001
FEV1, M (Q1, Q3) 1.60 (1.10, 2.21) 1.62 (1.12, 2.21) 1.60 (1.05, 2.19) Z =  − 0.504 0.614
FVC, M (Q1, Q3) 2.26 (1.66, 3.64) 2.20 (1.65, 3.45) 2.34 (1.70, 3.83) Z = 1.379 0.168
FEV1/FVC, Mean ± SD 67.25 ± 13.27 68.87 ± 13.48 63.36 ± 11.88 t = 4.845  < 0.001
FEV1 in predicted value FEV1, mean ± SD 56.81 (42.65, 67.80) 58.40 (43.70, 68.42) 52.60 (38.80, 65.70) Z =  − 3.076 0.002
Use of systemic glucocorticoid, n (%) χ2 = 6.465 0.011
 No 472 (74.21) 346 (77.06) 126 (67.38)
 Yes 164 (25.79) 103 (22.94) 61 (32.62)
Antibacterial agents, n (%) χ2 = 0.012 0.913
 No 13 (2.04) 9 (2.00) 4 (2.14)
 Yes 623 (97.96) 440 (98.00) 183 (97.86)
Oxygen therapy, n (%) χ2 = 3.903 0.048
 No 126 (19.81) 98 (21.83) 28 (14.97)
 Yes 510 (80.19) 351 (78.17) 159 (85.03)
Mechanical ventilation, n (%) χ2 = 4.276 0.039
 No 628 (98.74) 446 (99.33) 182 (97.33)
 Noninvasive ventilation 8 (1.26) 3 (0.67) 5 (2.67)
Open in a new tab

LAMA long-acting muscarinic antagonist, LABA long-acting β agonist, SAMA short-acting muscarinic antagonist, SABA short-acting β agonist, PDE4I phosphodiesterase 4 inhibitor, ICS inhaled corticosteroids, Hb hemoglobin, RBC red blood cells, WBC white blood cells, PLT platelets, NEUT neutrophil count, LYM lymphocyte count, MONO monocytes count, EOS eosinophil count, RDW red blood cell distribution width, ALT glutamic-pyruvic transaminase, AST glutamic oxalacetic transaminase, TBIL total bilirubin, ALB albumin, BUN blood urea nitrogen, Cr creatinine, mMRC modified Medical Research Council, CAT COPD assessment test, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity

Risk factors of readmission in patients with AECOPD within one year

Variables with statistical significance in comparisons of the baseline data were included in the multivariate logistic regression analysis. Backward stepwise regression method was adopted, and age and gender were adjusted. The results delineated that patient with acute exacerbations within the previous 1 year had a 4.086-fold higher risk of readmission than those without acute exacerbations within the previous 1 year (OR = 4.086, 95% CI 2.723–6.133, P < 0.001). Patients using LABA had a 4.550-fold higher risk of readmission than those not using LABA (OR = 4.550, 95% CI 1.587–13.042, P = 0.005). Patients receiving ICS decreased the risk of readmission by 0.773 times (OR = 0.227, 95% CI 0.076–0.672, P = 0.007) compared with those not receiving ICS. The risk of readmission was reduced by 0.015 times with the per unit increase of ALT (OR = 0.985, 95% CI 0.971–0.999, P = 0.042). Each 1-point increase in total CAT score was associated with a 1.091-fold increased risk of readmission (OR = 1.091, 95% CI 1.048–1.136, P < 0.001) (Table 3).

Table 3.

Predictors analysis of readmission

Variable β S.E Wald P OR 95% CI
Lower Upper
Intercept  − 2.374 0.753 9.942 0.002
Age  − 0.008 0.011 0.491 0.484 0.992 0.972 1.014
Gender
 Male Ref
 Female  − 0.216 0.208 1.076 0.299 0.806 0.535 1.212
Acute exacerbation in previous 1 year
 No Ref
 Yes 1.408 0.207 46.174  < 0.001 4.086 2.723 6.133
LABA
 No Ref
 Yes 1.515 0.537 7.951 0.005 4.550 1.587 13.042
ICS
 No Ref
 Yes  − 1.484 0.555 7.157 0.007 0.227 0.076 0.672
ALT  − 0.015 0.007 4.152 0.042 0.985 0.971 0.999
CAT Score 0.087 0.021 17.871  < 0.001 1.091 1.048 1.136
Open in a new tab

LABA long-acting β agonist, ICS inhaled corticosteroids, ALT glutamic-pyruvic transaminase, CAT COPD assessment test

The equilibrium test of training set and testing set

All samples were randomly divided into the training set and the testing set (7:3). The results of equilibrium analysis after division showed that there was no statistical significance in the differences of variables between the training set and the testing set (Table 4).

Table 4.

The equilibrium test of training set and testing set

Variable Description (n = 636) Training set (n = 445) Testing set (n = 191) Statistical magnitude P
Gender, n (%) χ2 = 0.383 0.536
 Male 425 (66.82) 294 (66.07) 131 (68.59)
 Female 211 (33.18) 151 (33.93) 60 (31.41)
Age, Mean ± SD 70.82 ± 9.88 70.62 ± 9.91 71.27 ± 9.80 t =  − 0.757 0.449
BMI, Mean ± SD 23.48 ± 2.95 23.42 ± 3.01 23.61 ± 2.79 t =  − 0.750 0.453
Acute exacerbation in previous 1 year, n (%) χ2 = 1.740 0.187
 No 430 (67.61) 308 (69.21) 122 (63.87)
 Yes 206 (32.39) 137 (30.79) 69 (36.13)
Smoking status, n(%) Z = 0.336 0.737
 Never smoked 321 (50.47) 229 (51.46) 92 (48.17)
 Smoked before 93 (14.62) 59 (13.26) 34 (17.80)
 Smoker at present 222 (34.91) 157 (35.28) 65 (34.03)
  Daily amount of smoking, M (Q1, Q3) 0.00 (0.00, 15.00) 0.00 (0.00, 12.00) 0.00 (0.00, 15.00) Z =  − 0.135 0.893
  Duration of smoking, M (Q1, Q3) 0.00 (0.00, 30.00) 0.00 (0.00, 30.00) 0.00 (0.00, 30.00) Z =  − 0.243 0.808
 Number of years of smoking packets, M (Q1, Q3) 0.00 (0.00, 21.00) 0.00 (0.00, 25.00) 0.00 (0.00, 20.00) Z =  − 0.133 0.894
LAMA, n(%) χ2 = 1.067 0.302
 No 479 (75.31) 330 (74.16) 149 (78.01)
 Yes 157 (24.69) 115 (25.84) 42 (21.99)
SAMA, n(%) χ2 = 0.861 0.353
 No 634 (99.69) 443 (99.55) 191 (100.00)
 Yes 2 (0.31) 2 (0.45) 0 (0.00)
LABA, n(%) χ2 = 0.035 0.852
 No 413 (64.94) 290 (65.17) 123 (64.40)
 Yes 223 (35.06) 155 (34.83) 68 (35.60)
SABA, n(%) χ2 = 0.189 0.664
 No 555 (87.26) 390 (87.64) 165 (86.39)
 Yes 81 (12.74) 55 (12.36) 26 (13.61)
PDE4I, n(%) χ2 = 0.129 0.720
 No 617 (97.01) 431 (96.85) 186 (97.38)
 Yes 19 (2.99) 14 (3.15) 5 (2.62)
ICS, n(%) χ2 = 0.101 0.751
 No 422 (66.35) 297 (66.74) 125 (65.45)
 Yes 214 (33.65) 148 (33.26) 66 (34.55)
Congestive heart-failure, n (%) χ2 = 0.004 0.950
 No 572 (89.94) 400 (89.89) 172 (90.05)
 Yes 64 (10.06) 45 (10.11) 19 (9.95)
Diabetes, n (%) χ2 = 2.515 0.113
 No 498 (78.30) 356 (80.00) 142 (74.35)
 Yes 138 (21.70) 89 (20.00) 49 (25.65)
Hypertension, n (%) χ2 = 0.507 0.476
 No 280 (44.03) 200 (44.94) 80 (41.88)
 Yes 356 (55.97) 245 (55.06) 111 (58.12)
Atrial fibrillation, n (%) χ2 = 0.124 0.725
 No 596 (93.71) 418 (93.93) 178 (93.19)
 Yes 40 (6.29) 27 (6.07) 13 (6.81)
Combined with other diseases, n (%) χ2 = 1.130 0.288
 No 432 (67.92) 308 (69.21) 124 (64.92)
 Yes 204 (32.08) 137 (30.79) 67 (35.08)
Systolic blood pressure, Mean ± SD 133.46 ± 17.34 132.66 ± 16.44 135.31 ± 19.16 t =  − 1.665 0.097
Diastolic blood pressure, Mean ± SD 78.73 ± 10.82 78.21 ± 10.42 79.95 ± 11.62 t =  − 1.859 0.063
Respiratory rate, Mean ± SD 19.28 ± 2.53 19.17 ± 2.41 19.52 ± 2.77 t =  − 1.604 0.109
Temperature, Mean ± SD 36.86 ± 0.56 36.85 ± 0.54 36.90 ± 0.60 t =  − 1.055 0.292
Heart rate, Mean ± SD 81.65 ± 11.35 81.40 ± 11.24 82.24 ± 11.60 t =  − 0.860 0.390
Hb, Mean ± SD 132.51 ± 17.26 132.36 ± 17.41 132.85 ± 16.88 t =  − 0.328 0.743
RBC, Mean ± SD 4.33 ± 0.55 4.32 ± 0.55 4.35 ± 0.54 t =  − 0.654 0.514
WBC, M (Q1, Q3) 6.90 (5.53, 8.93) 6.85 (5.53, 8.68) 7.18 (5.50, 9.64) Z = 1.141 0.254
PLT, M (Q1, Q3) 188.50 (151.75, 235.00) 189.00 (155.00, 234.00) 187.00 (144.50, 239.00) Z =  − 0.845 0.398
NEUT, M (Q1, Q3) 4.68 (3.53, 6.65) 4.54 (3.52, 6.41) 5.13 (3.54, 7.11) Z = 1.663 0.096
Percentage of neutrophils, Mean ± SD 70.54 ± 11.65 69.96 ± 11.43 71.90 ± 12.03 t =  − 1.926 0.055
LYM, M (Q1, Q3) 1.29 (0.91, 1.80) 1.28 (0.93, 1.80) 1.31 (0.85, 1.79) Z =  − 0.681 0.496
Percentage of lymphocytes, M (Q1, Q3) 19.42 (12.47, 27.13) 19.60 (12.80, 27.50) 18.90 (11.25, 26.30) Z =  − 1.593 0.111
MONO, M (Q1, Q3) 0.44 (0.33, 0.60) 0.44 (0.34, 0.60) 0.44 (0.33, 0.61) Z =  − 0.826 0.409
Percentage of monocytes, M (Q1, Q3) 6.30 (4.90, 8.00) 6.40 (5.00, 8.20) 6.10 (4.80, 7.80) Z =  − 1.907 0.057
EOS, M (Q1, Q3) 0.10 (0.03, 0.19) 0.10 (0.03, 0.19) 0.08 (0.03, 0.16) Z =  − 0.577 0.564
Percentage of eosinophils, M(Q1, Q3) 1.46 (0.40, 2.90) 1.50 (0.40, 3.00) 1.40 (0.40, 2.55) Z =  − 0.830 0.406
RDW, Mean ± SD 13.20 ± 1.05 13.20 ± 1.04 13.20 ± 1.06 t = 0.053 0.957
ALT, M (Q1, Q3) 15.50 (11.00, 23.00) 15.40 (11.00, 23.00) 15.60 (10.00, 23.35) Z =  − 0.244 0.807
AST, M (Q1, Q3) 18.00 (14.00, 23.10) 18.00 (14.30, 23.70) 17.30 (13.25, 22.20) Z =  − 1.658 0.097
TBIL, M (Q1, Q3) 9.35 (6.70, 13.30) 9.60 (6.80, 13.40) 9.00 (6.60, 12.45) Z =  − 0.492 0.623
ALB, Mean ± SD 39.89 ± 4.67 39.95 ± 4.78 39.74 ± 4.38 t = 0.521 0.602
BUN, M (Q1, Q3) 5.44 (4.45, 6.68) 5.47 (4.43, 6.77) 5.36 (4.51, 6.64) Z =  − 0.221 0.825
Cr, M (Q1, Q3) 76.20 (64.40, 93.75) 75.80 (64.00, 92.50) 78.70 (65.20, 93.95) Z = 1.035 0.301
Uric acid, M (Q1, Q3) 288.50 (226.00, 352.00) 289.00 (232.00, 355.00) 287.00 (215.50, 347.00) Z =  − 0.829 0.407
Hypersensitive C-reactive protein, M (Q1, Q3) 8.40 (2.00, 36.67) 8.00 (2.20, 34.40) 9.30 (1.75, 43.15) Z = 0.697 0.486
mMRC grade, n (%) Z = 1.634 0.102
 0 1 (0.16) 0 (0.00) 1 (0.52)
 1 138 (21.70) 103 (23.15) 35 (18.32)
 2 279 (43.87) 196 (44.04) 83 (43.46)
 3 189 (29.72) 131 (29.44) 58 (30.37)
 4 29 (4.56) 15 (3.37) 14 (7.33)
CAT score, Mean ± SD 20.28 ± 5.34 20.16 ± 5.19 20.58 ± 5.67 t =  − 0.917 0.360
FEV1, M (Q1, Q3) 1.60 (1.10, 2.21) 1.60 (1.09, 2.21) 1.64 (1.12, 2.20) Z = 0.081 0.936
FVC, M (Q1, Q3) 2.26 (1.66, 3.64) 2.23 (1.65, 3.60) 2.30 (1.67, 3.67) Z = 0.381 0.704
FEV1/FVC, Mean ± SD 67.25 ± 13.27 67.23 ± 13.17 67.30 ± 13.50 t =  − 0.060 0.952
FEV1 in predicted value FEV1, Mean ± SD 55.33 ± 17.82 55.81 ± 17.73 54.19 ± 17.97 t = 1.048 0.295
Use of systemic glucocorticoid, n (%) χ2 = 2.348 0.126
 No 472 (74.21) 338 (75.96) 134 (70.16)
 Yes 164 (25.79) 107 (24.04) 57 (29.84)
Antibacterial agents, n (%) χ2 = 1.642 0.200
 No 13 (2.04) 7 (1.57) 6 (3.14)
 Yes 623 (97.96) 438 (98.43) 185 (96.86)
Oxygen therapy, n (%) χ2 = 0.220 0.639
 No 126 (19.81) 86 (19.33) 40 (20.94)
 Yes 510 (80.19) 359 (80.67) 151 (79.06)
Mechanical ventilation, n (%) χ2 = 0.098 0.755
 No 628 (98.74) 439 (98.65) 189 (98.95)
 Noninvasive ventilation 8 (1.26) 6 (1.35) 2 (1.05)
Group, n (%) χ2 = 1.687 0.194
 Non-readmission group 449 (70.60) 321 (72.13) 128 (67.02)
 Readmission group 187 (29.40) 124 (27.87) 63 (32.98)
Open in a new tab

LAMA long-acting muscarinic antagonist, LABA long-acting β agonist, SAMA short-acting muscarinic antagonist, SABA short-acting β agonist, PDE4I phosphodiesterase 4 inhibitor, ICS inhaled corticosteroids, Hb hemoglobin, RBC red blood cells, WBC white blood cells, PLT platelets, NEUT neutrophil count, LYM lymphocyte count, MONO monocytes count, EOS eosinophil count, RDW red blood cell distribution width, ALT glutamic-pyruvic transaminase, AST glutamic oxalacetic transaminase, TBIL total bilirubin, ALB albumin, BUN blood urea nitrogen, Cr creatinine, mMRC modified Medical Research Council, CAT COPD assessment test, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity

Construction of logistic model and validation of the predicative value via the testing set

Variables with statistical differences were included in the logistic model. The stepwise backward method was used, and age and gender were included. The results were shown in Table 5. Patients with acute exacerbations within the previous 1 year had a 3.863 times higher risk of readmission than those without acute exacerbations within the previous 1 year (OR = 3.863, 95% CI 2.349–6.351, P < 0.001). LABA usage in patients increased the risk of readmission by 4.556 times (OR = 5.556, 95% CI 1.577–19.577, P = 0.008). ICS treatment decreased the risk of readmission by 0.753 than patients without ICS treatment (OR = 0.247, 95% CI 0.067–0.908, P = 0.035). Each 1-point increase in total CAT score was correlated with a 1.110-fold increased risk of readmission (OR = 1.110, 95% CI 1.055–1.168, P < 0.001).

Table 5.

Construction of logistic model

Variable β S.E Wald P OR 95% CI
Lower Upper
Intercept  − 2.551 0.925 7.600 0.006
Age  − 0.015 0.013 1.245 0.265 0.985 0.961 1.011
Gender
 Male Ref
 Female 0.063 0.253 0.062 0.803 1.065 0.649 1.749
Acute exacerbation in previous 1 year
 No Ref
 Yes 1.351 0.254 28.364  < 0.001 3.863 2.349 6.351
LABA
 No Ref
 Yes 1.715 0.643 7.121 0.008 5.556 1.577 19.577
ICS
 No Ref
 Yes  − 1.398 0.664 4.433 0.035 0.247 0.067 0.908
ALT  − 0.010 0.009 1.462 0.227 0.990 0.973 1.006
CAT Score 0.105 0.026 16.177  < 0.001 1.110 1.055 1.168
Open in a new tab

LABA long-acting β agonist, ICS inhaled corticosteroids, ALT glutamic-pyruvic transaminase, CAT COPD assessment test

The AUC value of the logistic model was 0.743 (95% CI 0.692–0.795) in the training set and 0.699 (95% CI 0.617–0.780) in the testing set (Fig. 2). The sensitivity was 0.702 (95% CI 0.621–0.782) in the training set and 0.667 (95% CI 0.550–0.783) in the testing set. The specificity was 0.726 (95% CI 0.677–0.775) in the training set and 0.664 (95% CI 0.582–0.746) in the testing set. The accuracy was 0.719 (95% CI 0.677–0.761) in the training set and 0.665 (95% CI 0.598–0.732) in the testing set. The cutoff point in the training set was 0.282 (Table 6).

Fig. 2.

Fig. 2

Open in a new tab

The ROC curve of showing the AUC value of the logistic model

Table 6.

The predicative value of logistic model

Parameters Data
Training set Testing set
Sensitivity (95% CI) 0.702 (0.621–0.782) 0.667 (0.550–0.783)
Specificity (95% CI) 0.726 (0.677–0.775) 0.664 (0.582–0.746)
AUC (95% CI) 0.743 (0.692–0.795) 0.699 (0.617–0.780)
Accuracy (95% CI) 0.719 (0.677–0.761) 0.665 (0.598–0.732)
Cut off 0.282 –
Open in a new tab

CI confidence interval, AUC area under the curve

Construction of XGBoost model and validation of the predicative value via the testing set

Variables with P < 0.1 were selected into the XGBoost model, and age and gender were also involved in. After GridSearchCV search tuning, the optimal parameters of the model were: tree depth: 2, number of trees: 50, learning rate: 0.01. The weight method was used to evaluate the importance of variables via the number of split nodes in the model tree. The results depicted that variables including acute exacerbation in previous 1 year, the CAT score, and SABA and LABA application were more important in the XGBoost model (Fig. 3).

Fig. 3.

Fig. 3

Open in a new tab

The weight method revealing the importance of variables in the XGBoost model

As delineated in Table 7, the AUC value of XGBoost model was 0.814 (95% CI 0.812–0.815) in the training set and 0.722 (95% CI 0.720–0.725) in the testing set (Fig. 4). The sensitivity was 0.702 (95% CI 0.621–0.782) in the training set and 0.635 (95% CI 0.516–0.754) in the testing set. The specificity was 0.826 (95% CI 0.784–0.867) in the training set and 0.750 (95% CI 0.675–0.825) in the testing set. The accuracy was 0.791 (95% CI 0.753–0.829) in the training set and 0.712 (95% CI 0.648–0.776) in the testing set. The cut of point in the training set was 0.451.

Table 7.

The predictive value of XGBoost model

Parameters Data
Training set Testing set
Sensitivity (95% CI) 0.702 (0.621–0.782) 0.635 (0.516–0.754)
Specificity (95% CI) 0.826 (0.784–0.867) 0.750 (0.675–0.825)
AUC (95% CI) 0.814 (0.812–0.815) 0.722 (0.720–0.725)
Accuracy (95%C I) 0.791 (0.753–0.829) 0.712 (0.648–0.776)
Open in a new tab

CI confidence interval, AUC area under the curve

Fig. 4.

Fig. 4

Open in a new tab

The ROC curve of showing the AUC value of the XGBoost model

Comparisons of the predictive abilities of the two prediction models

The logistic model and XGBoost model were used to establish the prediction model, and the performance of the models were compared. The AUC value of the logistic model was good in the training set but poor in the testing set while the XGBoost model showed good predictive abilities in both the training set and the testing set.

Discussion

This study collected the data of 650 patients with AECOPD and evaluated the risk factors for readmission within one year after treatment and discharge and constructed logistic model and XGBoost model to predict the risk of readmission within one year in AECOPD patients. The data revealed that acute exacerbation within the previous 1 year, LABA application, and the total CAT score were risk factors for readmission of AECOPD patients within one year while ICS application and higher ALT level were protective factors for readmission of AECOPD patients within one year. Additionally, we compared the predictive performances of logistic model and XGBoost model in predicting the risk of readmission within one year in AECOPD patients. The data delineated that the XGBoost model showed better predictive value.

Previously, the history of exacerbation was reported to an independent predictor for future exacerbations in patients [26]. A study of Bernabeu-Mora et al. indicated that the number of hospitalizations due to exacerbations in the previous year increased the risk of readmission by 4.44 times [27]. The results of these studies supported the findings in this study, showing that patients with acute exacerbations within the previous 1 year had a 4.086-fold higher risk of readmission than those without acute exacerbations within the previous 1 year. The CAT score is a questionnaire as a simple, and quick instrument for measuring the severity and impact of symptoms in COPD patients and determining of the appropriate treatment for those patients in clinical practice [28]. Multiple studies have revealed that CAT score had good internal consistency and test–retest reliability for both stable and exacerbating COPD [29]. The CAT scores were higher in patients with a history of frequent exacerbations [30]. Herein, patients with higher CAT scores were associated with a higher risk of readmission within one year. This maybe because higher CAT scores were correlated with higher concentrations of serum C-reactive protein and plasma fibrinogen, demonstrating that systemic inflammation were more serious in patients with higher CAT scores [31]. For AECOPD patients with high CAT score, timely intervention should be provided and after discharge, follow-up should be conducted regularly to prevent the occurrence of readmission. At present, the aim of the treatment for COPD patients was to prevent the deterioration of lung function and alleviate symptoms to decrease the risk of exacerbations [32] and short-acting bronchodilators and long-acting bronchodilators including LAMA, LABA, SAMA, SABA and ICS are frequently applied in the treatment of COPD [33]. SABA is often applied on an as-needed basis for symptom relief in COPD patients [34]. However, previous studies also identified that the application of SABA might have a higher risk of readmission for than other therapies including arformoterol tartrate [35, 36]. In our study, SABA was identified as an important variable influencing the risk of readmission in AECOPD patients within one year after discharge. ICS application reduce the frequency and severity of exacerbations [37]. In the present study, patients receiving ICS treatment decreased the risk of readmission than patients without ICS treatment, which was supported by previous studies. For patients with AECOPD, ICS treatment should be appropriately provided to prevent the occurrence of readmission of those patients [38]. Another study also delineated that the incidence of adverse events was higher in patients with LABA treatment (50.2%) than patients without LABA treatments and exacerbation of COPD was the most commonly reported adverse events [39]. This may result in the increase of readmission of patients, which gave support to the results of our study, depicting that LABA treatment may cause a higher risk of readmission in patients [34, 35]. For AECOPD patients, LABA usage should be applied with caution.

This study measured the predictors for readmission in patients with AECOPD within one year and established two prediction models including logistic model and XGBoost model. Random forest filling method was used for dealing with the missing values via constructing multiple decision trees, and the data after filling have randomness and uncertainty, which can better reflect the real distribution of these unknown data. Random forest filling method can be well applied to high-dimensional data filling because each branch node selects random partial features instead of all features in the process of decision tree construction. High accuracy and reliability of the data after filling were ensured. The validation of the predictive values of the models were performed in the testing set. Due to the small sample size in our study, the training set included 70% of the samples and the testing set included 30% of the participants. This split ensured enough samples for construction of more reliable models and meanwhile, there were still some samples to validate the performance of the model. The ROC curves were drawn to display the results of respective models. The AUC values of the logistic model were good in the training set but poor in the testing set while the XGBoost model showed good predictive abilities in both the training set and the testing set. This indicated that XGBoost model was better than logistic model in predicting the risk of readmission in patients with AECOPD within one year. Currently, the prediction of the risk of readmission in patients with AECOPD was focused on 30 days and 90 days after treatment and discharge [10–12, 40], but 30 days or 90 days could not actually represent the disease procession. The readmission of AECOPD patients within one year indicated the long-term prognosis of patients. A previous study established a prediction model for one-year readmission of COPD patients, but the AUC value was only 0.703 and the results were not validated [16]. Compared with the former prediction models, we compared logistic model and XGBoost model and found the AUC values of the XGBoost model were higher in both the training set and the testing set. The variables involved in our model were common for clinicians to collect, and based on these variables, XGBoost model can quickly predict the possibility of readmission in AECOPD patients after discharge within one year. In addition, our prediction model was uploaded to the GitHub with a free access for everyone (https://github.com/shipingchenmedicine123/XGBoost-model). The instructions for using the model was shown in Additional file 1: File 1. We welcome more clinicians to use our model to validate the results of our study. The findings of the current study might help early identify patients with a high risk of relapse and readmission, especially patients with moderate exacerbations, and provide timely intervention measures to reduce the incidence of AECOPD and readmission to improve the prognosis of COPD patients and delay the progression of the disease.

The strengths of this study were that we dealt with the missing data and no bias were obtained, and the results might be more reliable. Internal validation was also conducted to verify the results of the present study. There were several limitations in our study. Firstly, the sample size was small and collected from a single center, which might decrease the statistical power especially in some variables with limited samples, such as patients SABA usage. Therefore, results of our study might be interpreted with caution. Secondly, external validation of the findings was not performed. Thirdly, subgroup analysis was not performed on patients with mild exacerbations, moderate exacerbations and severe exacerbations. In the future, well-designed studies with large scale of sample size from muti-centers and external validations were required to verify the results of the present study.

Conclusions

In the current study, we constructed two models to predict the risk of readmission within one year in the AECOPD patients based on the predictors including acute exacerbation within the previous 1 year, LABA, ICS application, ALT level and the total CAT score. The results showed that the XGBoost model showed better predictive value in predicting the risk of readmission within one year in AECOPD patients than the logistic model. Variables including acute exacerbation in previous 1 year, the CAT score, and SABA and LABA application were more important in the XGBoost prediction model. The findings of our study might help identify patients with a high risk of readmission in patients with AECOPD within one year and provide timely interventions and treatment to prevent the reoccurrence of AECOPD.

Supplementary Information

12890_2021_1692_MOESM1_ESM.docx (13.6KB, docx)

Additional file 1: Instuctions for using the XGBoost.

Acknowledgements

Not applicable.

Abbreviations

COPD

Chronic obstructive pulmonary disease

AECOPD

Acute exacerbation of COPD

BMI

Body mass index

LAMA

Long-acting muscarinic antagonist

LABA

Long-acting β agonist

SAMA

Short-acting muscarinic antagonist

SABA

Short-acting β agonist

PDE4I

Phosphodiesterase 4 inhibitor

ICS

Inhaled corticosteroids

Hb

Hemoglobin

RBC

Red blood cells

WBC

White blood cells

PLT

Platelets

NEUT

Neutrophil count

LYM

Lymphocyte count

MONO

Monocytes count

EOS

Eosinophil count

RDW

Red blood cell distribution width

ALT

Glutamic-pyruvic transaminase

AST

Glutamic oxalacetic transaminase

TBIL

Total bilirubin

ALB

Albumin

BUN

Blood urea nitrogen

Cr

Creatinine

mMRC

Modified Medical Research Council

CAT

COPD assessment test

FEV1

Forced expiratory volume in 1 s

LVEF

Left ventricular ejection fraction

Authors' contributions

LC and SC designed the study. LC wrote the manuscript. SC collected, analyzed and interpreted the data. LC and SC critically reviewed, edited and approved the manuscript. Both authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study can be made available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

This study got the approval from the Ethics Committee of from the Second Affiliated Hospital of Nanjing Medical University, the approval number was (No. [2021]-KY-091-01). Written informed consent was obtained from all subjects before study entry.

Consent for publication

Written informed consent was obtained from all subjects before study entry.

Competing interests

The authors declare that they have no competing interests.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 Report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582. doi: 10.1164/rccm.201701-0218PP. [DOI] [PubMed] [Google Scholar]
  • 2.Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. The Lancet. 2012;379(9823):1341–1351. doi: 10.1016/S0140-6736(11)60968-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet (London, England) 2018;391(10131):1706–1717. doi: 10.1016/S0140-6736(18)30841-9. [DOI] [PubMed] [Google Scholar]
  • 4.Criner GJ, Bourbeau J, Diekemper RL, Ouellette DR, Goodridge D, Hernandez P, Curren K, Balter MS, Bhutani M, Camp PG, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147(4):894–942. doi: 10.1378/chest.14-1676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Jing Z, Chun C, Ning S, Hong Z, Bei H, Wan-Zhen Y. Systemic inflammatory marker CRP was better predictor of readmission for AECOPD than sputum inflammatory markers. Arch Bronconeumol. 2016;52(3):138–144. doi: 10.1016/j.arbres.2015.01.011. [DOI] [PubMed] [Google Scholar]
  • 6.Burkes RM, Donohue JF. An update on the global initiative for chronic obstructive lung disease 2017 guidelines with a focus on classification and management of stable COPD. Respir Care. 2018;63(6):749–758. doi: 10.4187/respcare.06174. [DOI] [PubMed] [Google Scholar]
  • 7.Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–963. doi: 10.1136/thoraxjnl-2011-201518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Jo YS, Rhee CK, Kim KJ, Yoo KH, Park YB. Risk factors for early readmission after acute exacerbation of chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2020;14:1753466620961688. doi: 10.1177/1753466620961688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Anbesse ZK, Mega TA, Tesfaye BT, Negera GZ. Early readmission and its predictors among patients treated for acute exacerbations of chronic obstructive respiratory disease in Ethiopia: a prospective cohort study. PLoS ONE. 2020;15(10):e0239665. doi: 10.1371/journal.pone.0239665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Goto T, Yoshida K, Faridi MK, Camargo CA, Jr, Hasegawa K. Contribution of social factors to readmissions within 30 days after hospitalization for COPD exacerbation. BMC Pulm Med. 2020;20(1):107. doi: 10.1186/s12890-020-1136-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Hakim MA, Garden FL, Jennings MD, Dobler CC. Performance of the LACE index to predict 30-day hospital readmissions in patients with chronic obstructive pulmonary disease. Clin Epidemiol. 2018;10:51–59. doi: 10.2147/CLEP.S149574. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Echevarria C, Steer J, Heslop-Marshall K, Stenton SC, Hickey PM, Hughes R, Wijesinghe M, Harrison RN, Steen N, Simpson AJ, et al. The PEARL score predicts 90-day readmission or death after hospitalisation for acute exacerbation of COPD. Thorax. 2017;72(8):686–693. doi: 10.1136/thoraxjnl-2016-209298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Cushen B, Greene G, MacHale E, Tompkins L, Boland F, Mouronte-Roibás C, Fernandez Villar JA, vanGeffen W, Kelly E, Costello RW. The COPD-2-HOME score: a novel tool to predict re-exacerbation in the 90 days following hospitalisation with an acute exacerbation of COPD (AECOPD). American Thoracic Society International Conference Abstracts.
  • 14.Kong CW, Wilkinson TMA: Predicting and preventing hospital readmission for exacerbations of COPD. ERJ Open Res. 2020;6(2). [DOI] [PMC free article] [PubMed]
  • 15.Njoku CM, Alqahtani JS, Wimmer BC, Peterson GM, Kinsman L, Hurst JR, Bereznicki BJ. Risk factors and associated outcomes of hospital readmission in COPD: a systematic review. Respir Med. 2020;173:105988. doi: 10.1016/j.rmed.2020.105988. [DOI] [PubMed] [Google Scholar]
  • 16.Wu YK, Lan CC, Tzeng IS, Wu CW. The COPD-readmission (CORE) score: a novel prediction model for one-year chronic obstructive pulmonary disease readmissions. J Formos Med Assoc Taiwan yi zhi. 2021;120(3):1005–1013. doi: 10.1016/j.jfma.2020.08.043. [DOI] [PubMed] [Google Scholar]
  • 17.Tunc HC, Sakar CO, Apaydin H, Serbes G, Gunduz A, Tutuncu M, Gurgen F. Estimation of Parkinson's disease severity using speech features and extreme gradient boosting. Med Biol Eng Compu. 2020;58(11):2757–2773. doi: 10.1007/s11517-020-02250-5. [DOI] [PubMed] [Google Scholar]
  • 18.Hou N, Li M, He L, Xie B, Wang L, Zhang R, Yu Y, Sun X, Pan Z, Wang K. Predicting 30-days mortality for MIMIC-III patients with sepsis-3: a machine learning approach using XGboost. J Transl Med. 2020;18(1):462. doi: 10.1186/s12967-020-02620-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Dull R, Dull S. Redundant medication use during acute exacerbation of chronic obstructive pulmonary disease in hospitalized patients. Int J Clin Pharm. 2020;42(5):1278–1285. doi: 10.1007/s11096-020-01064-7. [DOI] [PubMed] [Google Scholar]
  • 20.Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet (London, England) 2007;370(9589):786–796. doi: 10.1016/S0140-6736(07)61382-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Zhang Z, Wang J, Zheng Z, Chen X, Zeng X, Zhang Y, Li D, Shu J, Yang K, Lai N, et al. Genetic variants in the hedgehog interacting protein gene are associated with the FEV1/FVC ratio in southern Han Chinese subjects with chronic obstructive pulmonary disease. Biomed Res Int. 2017;2017:2756726. doi: 10.1155/2017/2756726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Zhong T, Zhuang Z, Dong X, Wong KH, Wong WT, Wang J, He D, Liu S. Predicting antituberculosis drug-induced liver injury using an interpretable machine learning method: model development and validation study. JMIR Med Inform. 2021;9(7):29226. doi: 10.2196/29226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Stekhoven DJ, Bühlmann P. MissForest–non-parametric missing value imputation for mixed-type data. Bioinformatics (Oxford, England) 2012;28(1):112–118. doi: 10.1093/bioinformatics/btr597. [DOI] [PubMed] [Google Scholar]
  • 24.Chen M, Yang Q, Xu Z, Luo B, Li F, Yu Y, Sun J. Survival analysis and prediction model for pulmonary sarcomatoid carcinoma based on SEER database. Front Oncol. 2021;11:630885. doi: 10.3389/fonc.2021.630885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Tang L, Li W, Zeng X, Wang R, Yang X, Luo G, Chen Q, Wang L, Song B. Value of artificial intelligence model based on unenhanced computed tomography of urinary tract for preoperative prediction of calcium oxalate monohydrate stones in vivo. Ann Transl Med. 2021;9(14):1129. doi: 10.21037/atm-21-965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Yii ACA, Loh CH, Tiew PY, Xu H, Taha AAM, Koh J, Tan J, Lapperre TS, Anzueto A, Tee AKH. A clinical prediction model for hospitalized COPD exacerbations based on "treatable traits". Int J Chron Obstruct Pulmon Dis. 2019;14:719–728. doi: 10.2147/COPD.S194922. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Bernabeu-Mora R, García-Guillamón G, Valera-Novella E, Giménez-Giménez LM, Escolar-Reina P, Medina-Mirapeix F. Frailty is a predictive factor of readmission within 90 days of hospitalization for acute exacerbations of chronic obstructive pulmonary disease: a longitudinal study. Ther Adv Respir Dis. 2017;11(10):383–392. doi: 10.1177/1753465817726314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648–654. doi: 10.1183/09031936.00102509. [DOI] [PubMed] [Google Scholar]
  • 29.Marchand E, Maury G. Evaluation of the COPD Assessment Test in patients with stable COPD. Rev Mal Respir. 2012;29(3):391–397. doi: 10.1016/j.rmr.2011.09.043. [DOI] [PubMed] [Google Scholar]
  • 30.Tu YH, Zhang Y, Fei GH. Utility of the CAT in the therapy assessment of COPD exacerbations in China. BMC Pulm Med. 2014;14:42. doi: 10.1186/1471-2466-14-42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Yao C, Wang L, Shi F, Chen R, Li B, Liu W, Feng M, Li S. Optimized combination of circulating biomarkers as predictors of prognosis in AECOPD patients complicated with Heart Failure. Int J Med Sci. 2021;18(7):1592–1599. doi: 10.7150/ijms.52405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Celli BR. Pharmacological therapy of COPD: reasons for optimism. Chest. 2018;154(6):1404–1415. doi: 10.1016/j.chest.2018.07.005. [DOI] [PubMed] [Google Scholar]
  • 33.Currie GP, Lipworth BJ. Inhaled treatment for chronic obstructive pulmonary disease: What's new and how does it fit? QJM Month J Assoc Phys. 2016;109(8):505–512. doi: 10.1093/qjmed/hcv212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Tavakoli H, Johnson KM, FitzGerald JM, Sin DD, Gershon AS, Kendzerska T, Sadatsafavi M. Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada. Int J Chron Obstruct Pulmon Dis. 2019;14:2003–2013. doi: 10.2147/COPD.S210897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Keshishian A, Xie L, Dembek C, Yuce H. Reduction in hospital readmission rates among Medicare beneficiaries with chronic obstructive pulmonary disease: a real-world outcomes study of nebulized bronchodilators. Clin Ther. 2019;41(11):2283–2296. doi: 10.1016/j.clinthera.2019.09.001. [DOI] [PubMed] [Google Scholar]
  • 36.Bollu V, Ernst FR, Karafilidis J, Rajagopalan K, Robinson SB, Braman SS. Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD. Int J Chron Obstruct Pulmon Dis. 2013;8:631–639. doi: 10.2147/COPD.S52557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Cho KH, Kim YS, Linton JA, Nam CM, Choi Y, Park EC. Effects of inhaled corticosteroids /long-acting agonists in a single inhaler versus inhaled corticosteroids alone on all-cause mortality, pneumonia, and fracture in chronic obstructive pulmonary disease: a nationwide cohort study 2002–2013. Respir Med. 2017;130:75–84. doi: 10.1016/j.rmed.2017.07.012. [DOI] [PubMed] [Google Scholar]
  • 38.Mirza S, Clay RD, Koslow MA, Scanlon PD. COPD guidelines: a review of the 2018 GOLD report. Mayo Clin Proc. 2018;93(10):1488–1502. doi: 10.1016/j.mayocp.2018.05.026. [DOI] [PubMed] [Google Scholar]
  • 39.Sethi S, Donohue JF, Ferguson GT, Barnes CN, Crater GD. Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials. Ther Adv Respir Dis. 2020;14:1753466620905278. doi: 10.1177/1753466620905278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Shin B, Kim SH, Yong SJ, Lee WY, Park S, Lee SJ, Lee SJ, Lee MK. Early readmission and mortality in acute exacerbation of chronic obstructive pulmonary disease with community-acquired pneumonia. Chron Respir Dis. 2019;16:1479972318809480. doi: 10.1177/1479972318809480. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

12890_2021_1692_MOESM1_ESM.docx (13.6KB, docx)

Additional file 1: Instuctions for using the XGBoost.

Data Availability Statement

The datasets used and/or analyzed during the current study can be made available from the corresponding author on reasonable request.

Articles from BMC Pulmonary Medicine are provided here courtesy of BMC

RESOURCES